Celularity announced that its expected net sales for the first quarter of 2024 are trending ahead of the expectations it announced in February for its advanced biomaterial products and biobanking businesses. “Expected net sales in the first quarter of 2024 trended up in both January and February and so far, are ahead of the quarterly net sales expectations we announced in early February,” said Celularity CEO and Founder Dr. Robert Hariri, M.D., Ph.D. “Plainly said, we believe the wound care market is adopting our products faster than we first anticipated, which if true should be reflected in continued sales growth, both within the traditional wound care market and from additional potential applications for our advanced biomaterial products. Celularity’s predecessor company was an early innovator in the field of placental-derived biomaterials, and today we continue to develop innovative, next-generation products in this technology. We continue to believe Celularity is uniquely positioned to leverage its diversified platform of technology across cellular and regenerative medicine indications beyond wound care.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CELU:
- Celularity data showing senescent cell elimination to be presented at ASGCT
- Celularity to Present Data Showing Senescent Cell Elimination by Off-the-Shelf Natural Killer Cells Derived from Human Placental Cells
- Celularity receives HCPCS Q code approval from U.S. CMS for Biovance 3L
- Celularity Submits Request to U.S. FDA for Orphan Drug Designation for PDA-002 Asset Treating Facioscapulohumeral Muscular Dystrophy
- Celularity submits request to FDA for orphan drug designation for PDA-002
